Waldenström macroglobulinemia: Development of diagnostic criteria and identification of prognostic factors

American Journal of Clinical Pathology

Volumn 116, Issue 3, 2001, Pages 420-428

  Owen, R G ^a   Barrans, S L ^a   Richards, S J ^a   O'Connor, S J M ^a   Child, J A ^a   Parapia, L A ^a   Morgan, G J ^a   Jack, A S ^a  

^a LEEDS GENERAL INFIRMARY   (United Kingdom)

Author keywords

Immunophenotype; Prognostic factors; Waldenstr m macroglobulinemia

Indexed keywords

CD19 ANTIGEN; CD20 ANTIGEN; CD23 ANTIGEN; CD5 ANTIGEN; COMMON ACUTE LYMPHOBLASTIC LEUKEMIA ANTIGEN; IMMUNOGLOBULIN;

ADULT; AGED; ARTICLE; BONE MARROW; CLINICAL FEATURE; DIAGNOSTIC ACCURACY; DISEASE CLASSIFICATION; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOPHENOTYPING; LABORATORY DIAGNOSIS; LYMPHOCYTIC INFILTRATION; MAJOR CLINICAL STUDY; MALE; MONOCLONAL IMMUNOGLOBULINEMIA; MULTIVARIATE ANALYSIS; PANCYTOPENIA; PERFORMANCE; PLASMA CELL; PRIORITY JOURNAL; PROGNOSIS; SURVIVAL RATE; THROMBOCYTE COUNT; WALDENSTROEM MACROGLOBULINEMIA;

ADULT; AGED; AGED, 80 AND OVER; ANTIGENS, CD; BONE MARROW; FEMALE; FLOW CYTOMETRY; HUMANS; IMMUNOPHENOTYPING; MALE; MIDDLE AGED; PROGNOSIS; SURVIVAL RATE; WALDENSTROM MACROGLOBULINEMIA;

EID: 0034855777     PISSN: 00029173     EISSN: None     Source Type: Journal    
DOI: 10.1309/4LCN-JMPG-5U71-UWQB     Document Type: Article

References (59)

1. Incipient myelomatosis or essential hyperglobulinemia with fibrinogenopenia: A new syndrome?
2. Waldenström's macroglobulinemia
3. Waldenström's macroglobulinemia: Clinical features, complications, and management
4. Waldenström's macroglobulinaemia: Laboratory diagnosis and treatment
5. Incidence of Waldenström's macroglobulinemia
6. Autoimmune thrombocytopenia in Waldenström's macroglobulinemia
7. Studies on monoclonal antibodies, I: The specificity and binding properties of a Waldenström macroglobulin with anti-G activity
8. Monoclonal macroglobulinemia in malignant lymphoma
9. The spectrum of IgM monoclonal gammopathy in 430 cases
10. Clinicopathological correlates of 1gM paraproteinemias
11. Proposals for the classification of chronic (mature) B and T lymphoid leukaemias
12. A revised European-American Classification of Lymphoid Neoplasms: A proposal from the International Lymphoma Study Group
13. World Health Organization Classification of Neoplastic Diseases of the Hematopoietic and Lymphoid Tissues: Report of the Clinical Advisory Committee meeting, Airlie House, Virginia, November 1997
14. A clinical evaluation of the International Lymphoma Study Group Classification of Non-Hodgkin's Lymphoma
15. Paraprotein status in lymphoplasmacytoid lymphoma/immunocytoma: Do all cases correspond to Waldenström's macroglobulinaemia
16. Immunocytoma: A retrospective analysis from St Bartholomew's Hospital, 1972 to 1996
17. VH gene analysis of clonally related IgM and IgG from human lymphoplasmacytoid B-cell tumors with chronic lymphocytic leukemia features and high serum monoclonal IgG
18. Nonparametric estimation from incomplete observations
19. Asymptotically efficient rank invariant test procedures
20. Regression models and life tables
21. Prognostic factors in Waldenström's macroglobulinemia: A report of 167 cases
22. Primary systemic amyloidosis: A rare complication of immunoglobulin M monoclonal gammopathies and Waldenström's macroglobulinemia
23. A predictive model for aggressive non-Hodgkin's lymphoma
24. Immunological phenotype of neoplasms involving the B cell in the last step of differentiation
25. Analysis of leucocyte differentiation antigens in blood and bone marrow from patients with Waldenström's macroglobulinaemia
26. Lymphoplasmacytoid lymphoma: An immunohistochemical study
27. Immunophenotyping of low-grade B-cell lymphoma in blood and bone marrow: Poor correlation between immunophenotype and cytological/histological classification
28. The immunological profile of B-cell disorders and proposal of a scoring system for the diagnosis of CLL
29. Follicular lymphomas contain clonally linked but phenotypically distinct neoplastic B-cell population in the interfollicular zone
30. Rituximab therapy in previously treated Waldenström's macroglobulinemia: Preliminary evidence of activity
31. European phase II study of rituximab (chimeric anti-CD20 monoclonal antibody) for patients with newly diagnosed mantle cell lymphoma and previously treated mantle cell lymphoma, immunocytoma and small B-cell lymphocytic lymphoma
32. Phenotypic and clinical evidence supports rituximab for Waldenström's macroglobulinemia
33. Study of prognosis in Waldenström's macroglobulinemia: A proposal for a simple binary classification with clinical and investigational utility
34. Prognostic factors in Waldenström macroglobulinemia: A report on 232 patients with the description of a new scoring system and its validation on 253 other patients
35. New approach to classifying non-Hodgkin's lymphomas: Clinical features of the major histologic subtypes
36. Fibrinogen and viscosity as risk factors for subsequent cardiovascular events in stroke survivors
37. Fibrinogen, viscosity and the 10-year incidence of ischaemic heart disease
38. Blood viscosity and risk of cardiovascular events: The Edinburgh Artery Study
39. Plasma viscosity and the risk of coronary heart disease: Results from the MONICA-Augsburg Cohort Follow-up Study 1984/85-1992
40. Association between plasma viscosity and all-cause mortality: Results from the MONICA-Augsburg Cohort Study 1984-1992
41. Bone marrow histology in Waldenström's macroglobulinaemia
42. Marginal zone B-cell lymphomas including mucosa-associated lymphoid tissue type lymphoma (MALT), monocytoid B-cell lymphoma and splenic marginal zone cell lymphoma and their relation to the reactive marginal zone
43. Similar patterns of Vk gene usage but different degrees of somatic mutation in hairy cell leukemia, prolymphocytic leukemia, Waldenström's macroglobulinemia and myeloma
44. Frequent somatic mutations in D and/or JH segments of Ig gene in Waldenström's macroglobulinemia and chronic lymphocytic leukemia (CLL) with Richter's syndrome but not in common CLL
45. Somatic hypermutation, clonal diversity, preferential expression of the VH 51p1/VL kv325 immunoglobulin gene combination in hepatitis C virus-associated immunocytomas
46. Insight into the origin and clonal history of B-cell tumors as revealed by analysis of immunoglobulin variable region genes
47. Should Waldenström's macroglobulinemia be considered part of the spectrum of marginal zone lymphoma?
48. Non-MALT marginal zone lymphomas: A description of clinical presentation and outcome in 124 patients
49. Clonal abnormalities in patients with Waldenström's macroglobulinemia with special reference to a Burkitt-type t(8;14)
50. Chromosome changes in 19 patients with Waldenström's macroglobulinemia
51. Concomitant partial tetrasomy 3q and trisomy 18 in Waldenström's macroglobulinemia
52. A case of t(8;14) with total and partial trisomy 3 in Waldenström's macroglobulinemia
53. Cytogenetic abnormalities in Waldenström's disease (WD): A single centre study on 45 cases
54. Primary macroglobulinemia with t(11;18)(q21;q21)
55. Detection of t(11;18) MALT lymphoma with double color FISH and/or RT-PCR
56. The apoptosis inhibitor gene AP12 and a novel 18q gene, MLT, are recurrently rearranged in the t(11;18)(q21;q21) associated with mucosa-associated lymphoid tissue lymphomas
57. t(9;14)(p13;q32) denotes a subset of low-grade non-Hodgkin's lymphoma with plasmacytoid differentiation
58. The t(9;14)(p13;q32) chromosomal translocation associated with lymphoplasmacytoid lymphoma involves the PAX-5 gene
59. Deregulated PAX-5 transcription from a translocated IgH promoter in marginal zone lymphoma